BiomX (PHGE) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
25 Feb, 2026Opening remarks and agenda
The meeting was called to order by the CEO, welcoming stockholders and outlining the purpose of the special meeting.
It was announced that the required quorum had not been achieved as of the meeting date.
Overview of voting outcomes
Due to the lack of quorum, the meeting was adjourned and rescheduled to March 11, 2026, at 8:00 A.M. Eastern Time, to allow more time for proxy solicitation and voting.
The record date for voting eligibility remains February 3, 2026.
Stockholders who have already voted do not need to vote again unless they wish to change their vote.
Votes will be counted according to the most recently submitted proxy instructions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BiomX
- Merger, $50M financing, and clinical progress drive 2025 milestones amid ongoing losses and delisting risk.PHGE
Q2 20248 Jul 2026 - BX211 and BX004 show strong efficacy; $12M financing supports key clinical milestones.PHGE
Q4 2024 & Study Result8 Jul 2026 - Shifted to defense/security tech, offering resale shares from acquisitions, with high dilution and financial risk.PHGE
Registration filing29 Jun 2026 - No auditor appointed for 2026; voting matters for the annual meeting remain unchanged.PHGE
Proxy filing22 Jun 2026 - Integrated AI and LADAR solutions drive growth in defense and security markets.PHGE
Investor presentation21 Jun 2026 - Vote on director election, equity plan amendment, and adjournment; board recommends approval.PHGE
Proxy filing8 Jun 2026 - Q1 2026 net loss was $19.1M amid a strategic pivot to defense and security tech.PHGE
Q1 202620 May 2026 - Vote sought on a new equity plan with evergreen increases and recent leadership changes disclosed.PHGE
Proxy filing25 Mar 2026 - Approval granted for issuance of shares tied to Series Y preferred stock and warrants.PHGE
EGM 202611 Mar 2026